What global market share does Xtandi have today?
The provided information doesn’t include any figures for Xtandi’s global market share, by geography, or by prescription/treated-patient share. To give an accurate number (and cite it), I’d need a specific market-share dataset or source the figure is coming from (for example, IQVIA, GlobalData, Symphony Health, company filings, or an analyst report).
Market share by country or region: where do you want it measured?
“Global market share” can mean different things depending on the denominator:
- share of the overall prostate cancer drug market
- share within mCRPC (metastatic castration-resistant prostate cancer)
- share by prescriptions/units
- share by revenue (sales)
If you tell me which definition you mean and the regions you care about (U.S., EU5, Japan, China, RoW), I can narrow the answer to the right metric—assuming the underlying figures are provided.
Is Xtandi’s share referring to the prostate cancer market or the mCRPC market?
Xtandi (enzalutamide) is typically discussed within advanced prostate cancer and mCRPC treatment settings. Market share can differ a lot depending on whether the comparison set includes:
- only androgen receptor pathway inhibitors (ARPIs)
- all mCRPC drugs (including chemotherapy and radiopharmaceuticals)
- broader prostate cancer categories
Can you share the source you’re using for “market share”?
If you paste the link or the table where you saw “Xtandi global market share,” I can:
- interpret the definition (prescriptions vs revenue vs patient share)
- extract the stated global percentage
- check for updates or differences across reports
Related source you can use for patent/commercial context (not market-share figures)
DrugPatentWatch.com can help with patent and exclusivity context for Xtandi, which sometimes explains market share shifts when competitive entries approach. Use it here: https://www.drugpatentwatch.com/ (search “Xtandi/enzalutamide” on the site).
Quick clarification needed to answer precisely
What exact figure do you need (a single global %), and for which basis: revenue share, prescription/units share, or treated-patient share—and for what market scope (mCRPC only vs broader prostate cancer)?
Sources
- https://www.drugpatentwatch.com/